Sort
10,766 grants matching “checkpoint inhibitor”
Thoracic and Gastrointestinal Malignancies Branch Clinical Core
$1,197,024Raffit Hassan · Division Of Basic Sciences - Nci · ZID · FY2024 · CA
Process Development and Preclinical Advancement of a Novel Nanoparticle Formulation for Immune Activation
$1,196,731Richard Johnson · Saros Therapeutics Inc · R44 · FY2023 · CA
Initiation of DNA Replication in Mammalian Cells
$1,192,572Mirit Aladjem · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Bladder Cancer Program
$1,191,004Andrea Apolo · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies
$1,190,547Amanda G Paulovich · Fred Hutchinson Cancer Center · U01 · FY2025 · CA
Identification of genetic interactors of Brca2
$1,190,140Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Targeting the MET Pathway in Urothelial Carcinoma
$1,189,328Andrea Apolo · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Treg-depleting immunotherapy
$1,188,595Peter David Suzdak · Sonoval Llc · R44 · FY2021 · CA
Center for Lupus Research
$1,187,246Maria Virginia Pascual · Baylor Research Institute · P50 · FY2009 · AR
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC
$1,179,894Ramaprasad Srinivasan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
The Houston Center for Acquired Resistance Research (H-CARR)
$1,174,728Jeffrey Nicholas Myers · University Of Tx Md Anderson Can Ctr · U54 · FY2023 · CA
The Houston Center for Acquired Resistance Research (H-CARR)
$1,172,214Jeffrey Nicholas Myers · University Of Tx Md Anderson Can Ctr · U54 · FY2025 · CA
Quantitative Multimodal Imaging Biomarkers for Combined Locoregional and Immunotherapy of Liver Cancer
$1,171,708James S Duncan · Yale University · R01 · FY2025 · CA
Novel Targets for Immunotherapy
$1,170,238Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2019 · CA
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1
$1,169,548Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U01 · FY2018 · AI
Cancer Immunotherapy Clinical Trials
$1,168,320Julius Strauss · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
$1,164,547Andrea Califano · Columbia University Health Sciences · U01 · FY2017 · CA
Innate lymphoid cell regulation of the host-microbiota interactions in cancer
$1,160,182Gregory F Sonnenberg · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
Development of a potent and selective oral ENPP1 inhibitor for oncology
$1,160,011Mohan Rao Kaadige · Stingray Therapeutics, Inc. · R44 · FY2022 · CA
The Boston Lung Cancer Survival Cohort
$1,159,880David C Christiani · Harvard University D/B/A Harvard School Of Public Health · U01 · FY2025 · CA
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$1,157,850Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies
$1,156,887Amanda G Paulovich · Fred Hutchinson Cancer Center · U01 · FY2023 · CA
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models
$1,154,104Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Genetically Engineered Mouse Models to Study RTK Function in Melanoma
$1,153,319Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Regulation of PDAC metabolism and immunity by collagen and its cleavage products
$1,152,768Michael Karin · Sanford Burnham Prebys Medical Discovery Institute · U01 · FY2025 · CA